Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone857-285-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.43 million
Profitability
Miscellaneous
Employees211
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions
What is Intellia Therapeutics' stock symbol?
Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."
How were Intellia Therapeutics' earnings last quarter?
Intellia Therapeutics Inc (NASDAQ:NTLA) announced its earnings results on Thursday, August, 1st. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.61) by $0.05. The company earned $11.10 million during the quarter, compared to analyst estimates of $7.15 million. Intellia Therapeutics had a negative net margin of 242.65% and a negative return on equity of 33.03%. Intellia Therapeutics's revenue was up 44.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.52) earnings per share. View Intellia Therapeutics' Earnings History.
When is Intellia Therapeutics' next earnings date?
What price target have analysts set for NTLA?
10 analysts have issued 1 year price objectives for Intellia Therapeutics' shares. Their forecasts range from $16.00 to $57.50. On average, they anticipate Intellia Therapeutics' stock price to reach $26.3571 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics.
What is the consensus analysts' recommendation for Intellia Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intellia Therapeutics.
What are Wall Street analysts saying about Intellia Therapeutics stock?
Here are some recent quotes from research analysts about Intellia Therapeutics stock:
- 1. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (8/8/2019)
- 2. Chardan Capital analysts commented, "We see the Alnylam experience as particularly relevant given parallels between the 2 companies’ pipelines (transthyretin amyloidosis, primary hyperoxaluria) as well as the use of lipid-nanoparticle (LNP) technology to deliver CRISPR/Cas RNAs (Intellia) or siRNA therapeutics (Alnylam) to the liver. Dr Sepp-Lorenzino also has experience in delivery of nucleotide therapies outside the liver. Given Intellia’s prior work on delivery of LNPs to the central nervous system, to us, this appointment could signal further non-liver pipeline expansion in the longer term. Is the tide of CRISPR management departures turning? In our 22 January 2019 research, we noted the trend of executive turnover/ departures at the helm of CRISPR gene editing companies that occurred over the course of 2018/early-19." (5/28/2019)
Has Intellia Therapeutics been receiving favorable news coverage?
News headlines about NTLA stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intellia Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Intellia Therapeutics.
Are investors shorting Intellia Therapeutics?
Intellia Therapeutics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 8,571,100 shares, a decrease of 9.4% from the June 30th total of 9,457,000 shares. Based on an average daily volume of 566,300 shares, the days-to-cover ratio is presently 15.1 days. Approximately 27.8% of the shares of the company are sold short. View Intellia Therapeutics' Current Options Chain.
Who are some of Intellia Therapeutics' key competitors?
Some companies that are related to Intellia Therapeutics include Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Quotient (QTNT), Heska (HSKA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX) and Riot Blockchain (RIOT).
What other stocks do shareholders of Intellia Therapeutics own?
Who are Intellia Therapeutics' key executives?
Intellia Therapeutics' management team includes the folowing people:
- Dr. John M. Leonard, Pres, CEO & Director (Age 62)
- Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)
- Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)
- Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)
- Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board
When did Intellia Therapeutics IPO?
(NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Intellia Therapeutics' major shareholders?
Intellia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (18.03%), Nikko Asset Management Americas Inc. (11.29%), BlackRock Inc. (6.98%), Vanguard Group Inc. (6.56%), Sumitomo Mitsui Trust Holdings Inc. (4.85%) and Morgan Stanley (1.83%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard and Nessan Bermingham. View Institutional Ownership Trends for Intellia Therapeutics.
Which institutional investors are selling Intellia Therapeutics stock?
NTLA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Ontario Teachers Pension Plan Board, Orbimed Advisors LLC, Bank of America Corp DE, WS Management Lllp, Elmwood Wealth Management Inc., BNP Paribas Arbitrage SA and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Intellia Therapeutics.
Which institutional investors are buying Intellia Therapeutics stock?
NTLA stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Vanguard Group Inc., ARK Investment Management LLC, BlackRock Inc., Renaissance Technologies LLC, Nuveen Asset Management LLC and Royal Bank of Canada. View Insider Buying and Selling for Intellia Therapeutics.
How do I buy shares of Intellia Therapeutics?
Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intellia Therapeutics' stock price today?
One share of NTLA stock can currently be purchased for approximately $17.43.
How big of a company is Intellia Therapeutics?
Intellia Therapeutics has a market capitalization of $846.05 million and generates $30.43 million in revenue each year. The company earns $-85,340,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.View Additional Information About Intellia Therapeutics.
What is Intellia Therapeutics' official website?
How can I contact Intellia Therapeutics?
Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]
MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
